Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press106110.17650/1726-9776-2008-4-3-9-15LECTUREЛЕКЦИЯFluorescent in situ hybridization: clinical use in oncourologyФлюоресцентная гибридизация in situ: практическое применение в онкоурологииBashkatovS. V.БашкатовС. В.
Russian Federation

Department of Radiotherapy and Surgery of Urologic Diseases

Obninsk

Отделение лучевого и хирургического лечения урологических заболеваний

Обнинск

SevankaevA. V.СеванькаевА. В.
Russian Federation

Radiation Cytogenetic Laboratory

Obninsk

Лаборатория радиационной цитогенетики

Обнинск

KaryakinO. B.КарякинО. Б.
Russian Federation

Department of Radiotherapy and Surgery of Urologic Diseases

Obninsk

Отделение лучевого и хирургического лечения урологических заболеваний

Обнинск

MihaylovaG. F.МихайловаГ. Ф.
Russian Federation

Radiation Cytogenetic Laboratory

Obninsk

Лаборатория радиационной цитогенетики

Обнинск

GolubYe. V.ГолубЕ. В. 
Russian Federation

Radiation Cytogenetic Laboratory

Obninsk

Лаборатория радиационной цитогенетики

Обнинск

State Enterprise Medical Radiological Research Center, Russian Academy of Medical SciencesГУ МРНЦ РАМН30092008439151402202014022020https://oncourology.abvpress.ru/oncur/article/view/1061

Tumor markers for diagnosis of bladder cancer and defining the prognosis of the disease have been actively studied for past decade. FISH-study demonstrates the highest sensitivity and specificity. Abbot Company has developed a diagnostic test system «UroVision» which includes colored DNA-probes referring to 3, 7, 17 and 9p21 chromosomes. This system use provides clinicians with insights into an early diagnosis, prognosis and monitoring of efficacy of anticancer therapy.

.

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М.; 2005.Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2003 г. М.; 2005.2. Shahin O., Thamann G.N., Rentsch C. et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Gurein for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169(1);96—100.Shahin O., Thamann G.N., Rentsch C. et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Gurein for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169(1);96—100.3. Reeder J.E., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 abberations by fluorescence in situ hybridization of irrigation speciment from bladder cancer patients. Urology 1998;51 (5A Suppl):58—61.Reeder J.E., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 abberations by fluorescence in situ hybridization of irrigation speciment from bladder cancer patients. Urology 1998;51 (5A Suppl):58—61.4. Inoue T., Nasu Y., Tsushima T. et al. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer. Urol Res 2000;28(1):57—61.Inoue T., Nasu Y., Tsushima T. et al. Chromosomal numerical aberrations of exfoliated cells in the urine detected by fluorescence in situ hybridization: clinical implication for the detection of bladder cancer. Urol Res 2000;28(1):57—61.5. Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57(4):811—5.Ishiwata S., Takahashi S., Homma Y. et al. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001;57(4):811—5.6. Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization idenifies more aggressive types of primarily noninvasive ( stage Ta) bladder cancer. J Urol 1997;157:2116—9.Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization idenifies more aggressive types of primarily noninvasive ( stage Ta) bladder cancer. J Urol 1997;157:2116—9.7. Marano A., Pan Y., Li C. et al. Chromosomal numerical aberration detected by fluorescence in situ hybridization on bladder washing from patients with bladder cancer. Eur Urol 2000;37(3):358—65.Marano A., Pan Y., Li C. et al. Chromosomal numerical aberration detected by fluorescence in situ hybridization on bladder washing from patients with bladder cancer. Eur Urol 2000;37(3):358—65.8. Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization bladder cancer: comparative analysis with cytology , cytogenetics and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997;3(12 Pt 1):2317—28.Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization bladder cancer: comparative analysis with cytology , cytogenetics and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997;3(12 Pt 1):2317—28.9. Awata S., Sakagami H., Tozawa K. et al. Aberration chromosome 8 and 11 in bladder cancer detected by fluorescence in situ hybridization. Urol Res 2000;28(3):185—90.Awata S., Sakagami H., Tozawa K. et al. Aberration chromosome 8 and 11 in bladder cancer detected by fluorescence in situ hybridization. Urol Res 2000;28(3):185—90.10. Cajulis R.S., Haines G.K., Frias-Hidvegi D. et al. Cytology, flow cytometry image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washing. Diagn Cytophatol 1995;13(3):214—24.Cajulis R.S., Haines G.K., Frias-Hidvegi D. et al. Cytology, flow cytometry image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washing. Diagn Cytophatol 1995;13(3):214—24.11. Jiang F., Caraway N.P., Sabichi A.L. et al. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 2003;20;106(5):661—5.Jiang F., Caraway N.P., Sabichi A.L. et al. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer 2003;20;106(5):661—5.12. Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1):8—10.Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1):8—10.13. Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-control and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107—13.Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-control and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107—13.14. Erbersdobler A., Friedrich M.G., Schwaibold H. et al. Microsatellite alterations at chromosomes 9p, 13q and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Oncol Res 1998;10(8):415—20.Erbersdobler A., Friedrich M.G., Schwaibold H. et al. Microsatellite alterations at chromosomes 9p, 13q and 17p in nonmuscle-invasive transitional cell carcinomas of the urinary bladder. Oncol Res 1998;10(8):415—20.15. Sokolova I.A., Halling K.C., Tenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116—23.Sokolova I.A., Halling K.C., Tenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116—23.16. Halling K.C., King W., Sokolova I.A. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in the urine. J Urol 2002;167(15):2001—6.Halling K.C., King W., Sokolova I.A. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in the urine. J Urol 2002;167(15):2001—6.17. Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164(5):1768—75.Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164(5):1768—75.18. Placer J., Espinet B., Salido M. et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42(6):547—52.Placer J., Espinet B., Salido M. et al. Clinical utility of a multiprobe FISH assay in voided urine specimens for detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol 2002;42(6):547—52.19. Veeranachaneni R., Nordberg M.L., Shi R. et al. Evaluation of fluorescence in situ hybridization as an ancillary tool urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28(6):301—7.Veeranachaneni R., Nordberg M.L., Shi R. et al. Evaluation of fluorescence in situ hybridization as an ancillary tool urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol 2003;28(6):301—7.20. Jones J.S. DNA-based molecular cytology for bladder cancer surveillance. Urology 2006;67(3 Suppl 1):35—45; discussion 45—7.Jones J.S. DNA-based molecular cytology for bladder cancer surveillance. Urology 2006;67(3 Suppl 1):35—45; discussion 45—7.21. Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116(1):79—86.Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116(1):79—86.22. Sarosdy M.F., Schellhammer P., Bokisky G. et al. Clinical evaluation of a multi-target fluorescence in situ hybridization assay for detection of bladder cancer. J Urol 2002;168(5):1950—4.Sarosdy M.F., Schellhammer P., Bokisky G. et al. Clinical evaluation of a multi-target fluorescence in situ hybridization assay for detection of bladder cancer. J Urol 2002;168(5):1950—4.23. Scacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients bladder cancer and atypical or negative urine cytology. J Urol 2003;169(6):2101—5.Scacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients bladder cancer and atypical or negative urine cytology. J Urol 2003;169(6):2101—5.24. Friedrich M.G., Toma M.I., Hellstern A. et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive teat for detecting bladder cancer. BJU Int 2003;92(9):911—4.Friedrich M.G., Toma M.I., Hellstern A. et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive teat for detecting bladder cancer. BJU Int 2003;92(9):911—4.25. Degtyar P., Neulander E., Zirkin H. et al. Fluorescence in situ hybridization performed on exfoliated urothelial cell in patients with transitional cell carcinomas of the bladder. Urology 2004;63(2):398—401.Degtyar P., Neulander E., Zirkin H. et al. Fluorescence in situ hybridization performed on exfoliated urothelial cell in patients with transitional cell carcinomas of the bladder. Urology 2004;63(2):398—401.26. Varella-Garcia M., Akduman B., Sunpaweravong P. et al. The UroVysion fluorescence in situ hybridization assay is an effective tool for recurrence of bladder cancer. Urol Oncol 2004;22(1):16—9.Varella-Garcia M., Akduman B., Sunpaweravong P. et al. The UroVysion fluorescence in situ hybridization assay is an effective tool for recurrence of bladder cancer. Urol Oncol 2004;22(1):16—9.27. van Rhijn W.G., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736—48.van Rhijn W.G., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736—48.28. Marin-Aguilera M., Mengual L., Ribal M.J. et al. Utility of fluorescent in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 2007;51(2):409—15.Marin-Aguilera M., Mengual L., Ribal M.J. et al. Utility of fluorescent in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol 2007;51(2):409—15.29. Spruk C.H., Ohneseit P.F., Gonzalez-Zulueta M. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54(3):784—8.Spruk C.H., Ohneseit P.F., Gonzalez-Zulueta M. et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54(3):784—8.30. Pycha A., Lodde M., Comploj E. et al. Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004;63(3):472—5.Pycha A., Lodde M., Comploj E. et al. Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 2004;63(3):472—5.31. Mian C., Lodde M., Comploj E. et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006;59(9):984—7.Mian C., Lodde M., Comploj E. et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006;59(9):984—7.32. Sauter G., Mihatsch M.J. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol 1998;185(4):339—41.Sauter G., Mihatsch M.J. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol 1998;185(4):339—41.33. Takahashi T. et al. Predicting urothelial carcinoma recurrences with fluorescence in situ hybridization analysis of urine. J Urol 2002;167(Suppl):162, abstr 651.Takahashi T. et al. Predicting urothelial carcinoma recurrences with fluorescence in situ hybridization analysis of urine. J Urol 2002;167(Suppl):162, abstr 651.34. Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173(2):401—4.Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173(2):401—4.35. Mengual L., Marin-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with BCG therapy. Eur Urol 2007;52(3):752—9, abstr.Mengual L., Marin-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with BCG therapy. Eur Urol 2007;52(3):752—9, abstr.